Drugs /

fulvestrant

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
fulvestrant
Trade Name(s):
Faslodex
NCI Definition [1]:
A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for fulvestrant

Fulvestrant has been investigated in 128 clinical trials, of which 95 are open and 33 are closed. Of the trials investigating fulvestrant, 1 is early phase 1 (1 open), 31 are phase 1 (25 open), 11 are phase 1/phase 2 (7 open), 63 are phase 2 (45 open), 1 is phase 2/phase 3 (1 open), 19 are phase 3 (16 open), 1 is phase 4 (0 open), and 1 is no phase specified (0 open).

ER Positive, HER2 Negative, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for fulvestrant clinical trials.

Breast carcinoma, invasive breast carcinoma, and breast adenocarcinoma are the most common diseases being investigated in fulvestrant clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Fulvestrant
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Fulvestrant
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating fulvestrant and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Faslodex, zm-182780, 129453-61-8, 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol, fulvestrant (substance), 7a-[9-[(4,4,5,5,5,-pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol, zd9238, ici-182780, fulvestrant [chemical/ingredient], 719276, ici 182,780, zm 182780, ici182780, fulvestrant (product), ici 182780, fulvestrant, fulvestrant, faslodex(ici 182,780)
Drug Categories [2]:
Estrogen receptor antagonists
Drug Target(s) [2]:
ESR1, ESR2
NCIT ID [1]:
C1379
SNOMED ID [1]:
F-B0511

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.